-+ 0.00%
-+ 0.00%
-+ 0.00%

ENGENE THERAPEUTICS - DETALIMOGENE SHOWS FAVORABLE TOLERABILITY WITH 2% SERIOUS TREATMENT-RELATED ADVERSE EVENTS

Reuters·11/11/2026 21:05:07